FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Aura bids to join the bladder cancer crowd
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
ELCC 2025 – subQ Keytruda heads towards approval
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
AACR 2025 preview – Roche's TIGIT postmortem
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
Elevation goes down on Claudin disaster
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
Imfinzi puts its flag on the Matterhorn
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
Merck takes on the TROP2 leaders again in breast cancer
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
